Carolina Alves Costa Silva's research while affiliated with La Ligue contre le cancer and other places

... Additionally, a recent study employed untargeted metabolomic analysis of the plasma of CM patients before treatment with anti-PD1 therapy and defined metabolic profiles associated with response to treatment [12]. Finally, multiple studies have explored the interaction between the microbiome, metabolomics, and the immune system [13,14]. Consequently, metabolites have emerged as potential biomarkers for treatment response, particularly in relation to immune checkpoint inhibitors (ICI). ...

... Although much emphasis has been placed on the central role of the intestinal microflora, which is the most diverse and quantitatively abundant microbiota, other microbial communities including those of the bladder and the skin may play an important role in determining anticancer immune responses as well 4,5 . In a fascinating paper that was recently published in Science, Chen et al. demonstrate that, in mice, Staphylococcus epidermidis can be genetically manipulated to express tumor antigens and then used to prevent or treat cancers expressing such antigens 6 . ...

... Here, male colorectal cancer patients with metastatic disease showed muscle loss of À8.3%/100 days [25], testicular cancer patients showed muscle loss up to À11.9%/100 days [20,21], and four new studies in neoadjuvant chemotherapy for esophageal/esophagogastric cancer, which has a high proportion of male individuals [16][17][18][19], showed relatively high intensity of muscle change (À7.2% to À9%/100 days). Muscle loss in the intermediate range were seen in a series of single reports, including Hodgkin's Lymphoma (À5.6%/ 100 days) [22], neoadjuvant chemotherapy for advanced ovarian cancer (6%/100 d) [15], curative intent chemoradiotherapy for head and neck cancer (À3.8%/100 days) [26] and targeted therapy cabozantinib in renal cell carcinoma (À4.6%/100 days) [27]. ...

... For instance, PCa patients receiving oral androgen receptor axis-targeted therapies showed a high abundance of Akkermansia muciniphila [8], which is associated with anti-PD-L1 immunotherapy [9]. Recent mouse experiments have demonstrated that ADT can reverse the reduction of Akkermansia muciniphila in PCa-bearing mice and oral administration of Akkermansia muciniphila, in turn, can enhance ADT efficacy and inhibit disease progression [10]. However, some studies have linked the gut microbiome to the side effects of ADT and hormone resistance. ...

... Early appearance of T cells reactive to peptide pools of the ancestral SARS-CoV2 strain correlates with a shorter duration of infection (5). Fahrner and colleagues reported a correlation between preexisting (before 2020) SARS-CoV-2-specific T-cell immune responses with a type 2 helper or cytotoxic (Th2/ Tc2) cytokine profile and susceptibility to infection with SARS-CoV-2 or reinfection by VOC (5). Moreover, although the breadth of the peptide recognition profile across the ORFeome did not correlate with infections during the first wave of the pandemic, a type 1 helper or cytotoxic (Th1/ Tc1) response selective for the S1-RBD region appeared to be essential for protection against BTI (5). ...

... Biomarkers represent a key component in the future of immuno-oncology; however, it is important to first find the most favorable markers because giving unnecessary immunotherapy could delay surgery and lead to cancer progression [29]. Some of these future markers could include radiomics [71,72], T-cell receptor repertoire and immunophenotype [73], intestinal microbiota [74], KEAP1, TP53 mutations [75] and mutational signature [76,77], to name a few. It is important to consider nonstandard biomarkers used in advanced cases of NSCLC that could be useful in the early setting as well; these include APOBEC, which has proven to predict the benefit of immunotherapy in NSCLC [78]. ...

... A recent report [82] showed that tumors impact gut motility by modulating betaadrenergic receptors. Varying the speed of passage likely changes the redox environment of the GI tract [83], suggesting that the redox state of redox-labile metabolites may change in breast cancer patients. ...

... Definitions of these terms are mentioned in "methods." TTF refers to the duration between the beginning of immunotherapy to drug discontinuation for any reason, including toxicity, disease progression, and even death (64). The TGR-dependent definition of HPD in eligible studies included "TGR post /TGR pre ≥ 2" or "TGR post /TGR pre ≥ 4," whereas certain studies define HPD as "(TGR post -TGR pre) / TGR pre ≥ 50%" or "> 40% increase in DTGR." ...

... The role of polyamine catabolism is involved in diverse cellular processes, including gene expression, protein synthesis, and oxidative stress regulation [44], as well as the genesis of disorders like cerebral ischemia and acute liver injury [45,46]. Recent studies have even highlighted increased levels of acetylpolyamine in the context of COVID-19 and trauma-related infections [47,48], further supporting the potential utility of polyamine catabolic products as non-invasive diagnostic markers. Moreover, the polyamine spermidine has been linked to enhanced mitochondrial respiratory function via eIF5A hypusination [49][50][51]. ...

... Three (50%) children had at least one underlying condition and none were immunocompromised. Although prolonged viral shedding is not rare among immunocompromised patients [34][35][36], viral shedding in the respiratory tract beyond 90 days in immunocompetent individuals is uncommon [37,38], suggesting that these cases represented true reinfections. ...